<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006114</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068126</org_study_id>
    <secondary_id>FRE-GERCOR-NONA-U98-1</secondary_id>
    <secondary_id>EU-20025</secondary_id>
    <nct_id>NCT00006114</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      patients who have metastatic prostate cancer that has not responded to hormone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of the combination of mitoxantrone and vinorelbine in terms of
           response rate, progression free survival, overall survival, and quality of life in
           patients with metastatic hormone refractory adenocarcinoma of the prostate.

        -  Determine the toxicities of this treatment regimen in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive vinorelbine IV on days 1 and 8 and mitoxantrone IV on day 8. Treatment
      repeats every 3 weeks for up to 9 courses in the absence of disease progression or
      unacceptable toxicity.

      Quality of life is assessed prior to treatment, prior to each course, and then at 2 months
      after study completion.

      Patients are followed every 3 months until disease progression.

      PROJECTED ACCRUAL: A total of 14-39 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage IV hormone refractory adenocarcinoma
             of the prostate

          -  Progressive disease despite hormonal therapy or orchiectomy

          -  No brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 80

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  Absolute neutrophil count at least 2,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 9 g/dL

        Hepatic:

          -  Alkaline phosphatase no greater than 2 times upper limit of normal (ULN) (unless bone
             metastasis)

          -  Bilirubin less than 2 times ULN

        Renal:

          -  Creatinine less than 2 times ULN

        Cardiovascular:

          -  Adequate cardiac function

        Other:

          -  No other prior malignancy except curatively treated basal or squamous cell skin cancer
             or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  Prior corticosteroids allowed if started at least 8 weeks prior to study

        Radiotherapy:

          -  At least 8 weeks since prior extensive radiotherapy

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Wendling, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Amiens</city>
        <zip>80054 Cedex 1</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gouin</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Perpetuel Secours</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Laennec</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Toulon - La Seyne/Mer</name>
      <address>
        <city>Toulon - Cedex</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 26, 2011</last_update_submitted>
  <last_update_submitted_qc>February 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

